Novartis Oncology VP of Risk Salaries in New York | Comparably
At Novartis Oncology, we are passionate about the discovery and development of innovative medicines. read more
EMPLOYEE
PARTICIPANTS
14
TOTAL
RATINGS
161

Novartis Oncology VP of Risk Salaries in New York

The average Novartis Oncology VP of Risk in New York earns an estimated $143,821 annually. Novartis Oncology's VP of Risk compensation is $866 more than the US average for a VP of Risk.

In New York, The Legal Department at Novartis Oncology earns $7,169 more on average than the Marketing Department.

Last updated 3 years ago.

$46k
$85k
$116k
$143k
$194k
$250k
$143,821
Average Compensation
$143,821
avg. base

VP of Risk Salaries at Novartis Oncology

In New York, VPs of Risk earn $25,265 more than Contracts Specialists, and $54,240 less than Corporate Counsels.

General Counsel
$206k*
Corporate Counsel
$198k*
Contracts Specialist
$119k*
Paralegal
$70k*
* estimated salary

Compensation at Novartis Oncology by Department

In New York, The Legal Department averages $7,169 more than the Marketing Department, and $7,269 less than the HR Department

HR
$109,931 Avg. total comp.
+$7k
Legal
$102,662 Avg. total comp.
Marketing
$95,493 Avg. total comp.
-$7k

VP of Risk Compensation by Gender (All Companies)

The average female VP of Risk at companies similar size to Novartis Oncology reported making $104,000, while the average male VP of Risk at similar sized companies reported making $157,000.

VP of Risk Compensation by Ethnicity (All Companies)

The average Hispanic or Latino VP of Risk at companies similar size to Novartis Oncology reported making $160,000, while the average Caucasian VP of Risk at similar sized companies reported making $132,000.

How VPs of Risk at Novartis Oncology Rate Their Compensation

The majority of VPs of Risk at Novartis Oncology believe they're not compensated fairly. 100% of VPs of Risk at Novartis Oncology say they receive annual bonuses, and the vast majority (83%) are satisfied with their benefits. See more compensation ratings at Novartis Oncology

×
Rate your company